A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative

Purpose: Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10-20%)...

Descripción completa

Detalles Bibliográficos
Autores: Leon Rapoport, B., Garcia-Morillo, M., Font, C., Samoon, Z., Jabbar, A.A., Kourie, H.R., Kayumba, A., Esposito, F., Popescu, R.A., García. Gómez, Jesús, Heyman, L., Smit, T., Krendyukov, A., Mathieson, N., Cooksley, T., Anderson, R., Klastersky, J.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/20999
Acceso en línea:https://portalcientifico.sergas.gal//documentos/6550da4c92517a5a7db95456
http://hdl.handle.net/20.500.11940/20999
Access Level:acceso abierto
Palabra clave:Humans
Middle Aged
Prospective Studies
Neoplasms
Granulocyte Colony-Stimulating Factor
Medical Oncology
Febrile Neutropenia
Antineoplastic Combined Chemotherapy Protocols
AS Ourense
CHUO
id ES_07dca02db04f3b11db7d66ac8ababe42
oai_identifier_str oai:runa.sergas.gal:20.500.11940/20999
network_acronym_str ES
network_name_str España
repository_id_str
spelling A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiativeLeon Rapoport, B.Garcia-Morillo, M.Font, C.Samoon, Z.Jabbar, A.A.Kourie, H.R.Kayumba, A.Esposito, F.Popescu, R.A.García. Gómez, JesúsHeyman, L.Smit, T.Krendyukov, A.Mathieson, N.Cooksley, T.Anderson, R.Klastersky, J.HumansMiddle AgedProspective StudiesNeoplasmsGranulocyte Colony-Stimulating FactorMedical OncologyFebrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsAS OurenseCHUOPurpose: Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10-20%) of FN would develop ? 1 episode of FN with a commonly used chemotherapy regimen in clinical practice. Methods: This prospective, real-world, observational, multinational, multicenter study (December 2016-October 2019) recruited patients with solid tumors or Hodgkin's/non-Hodgkin's lymphoma. Patients receiving chemotherapy with intermediate risk of FN, but not G-CSF as primary prophylaxis were included and observed for the duration of the chemotherapy (? 6 cycles and ? 30 days after the last chemotherapy administration). Results: In total, 364 patients (median age, 56 years) with 1601 cycles of chemotherapy were included in the analysis. The incidence of FN was 5% in cycle 1, 3% in cycles 2-3, and 1% in cycles 4-6. The rate of patients with ? 1 episode of FN was 9%, and 59% of FN events were reported during cycle 1. The rate of grade 4 neutropenia in cycle 1 was 11%, and 15% of patients experienced ? 1 episode of grade 4 neutropenia. Conclusions: Overall, the incidence of FN was low, with a high incidence in cycle 1 and a decrease in the subsequent cycles. These results provide the real FN risk for common chemotherapy regimens in patients generally excluded from clinical trials. Prophylactic G-CSF in intermediate-risk patients could be considered as per clinician's judgement.We thank patients and their families, investigators, and staff from all the participating sites. We thank Saurabh Agarwal, PhD, and Kavita Garg, PhD, CMPP (TM), of Novartis Healthcare Pvt. Ltd. for providing medical writing assistance with this manuscript.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/6550da4c92517a5a7db95456http://hdl.handle.net/20.500.11940/20999reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/209992026-06-12T08:40:47Z
dc.title.none.fl_str_mv A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
title A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
spellingShingle A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
Leon Rapoport, B.
Humans
Middle Aged
Prospective Studies
Neoplasms
Granulocyte Colony-Stimulating Factor
Medical Oncology
Febrile Neutropenia
Antineoplastic Combined Chemotherapy Protocols
AS Ourense
CHUO
title_short A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
title_full A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
title_fullStr A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
title_full_unstemmed A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
title_sort A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
dc.creator.none.fl_str_mv Leon Rapoport, B.
Garcia-Morillo, M.
Font, C.
Samoon, Z.
Jabbar, A.A.
Kourie, H.R.
Kayumba, A.
Esposito, F.
Popescu, R.A.
García. Gómez, Jesús
Heyman, L.
Smit, T.
Krendyukov, A.
Mathieson, N.
Cooksley, T.
Anderson, R.
Klastersky, J.
author Leon Rapoport, B.
author_facet Leon Rapoport, B.
Garcia-Morillo, M.
Font, C.
Samoon, Z.
Jabbar, A.A.
Kourie, H.R.
Kayumba, A.
Esposito, F.
Popescu, R.A.
García. Gómez, Jesús
Heyman, L.
Smit, T.
Krendyukov, A.
Mathieson, N.
Cooksley, T.
Anderson, R.
Klastersky, J.
author_role author
author2 Garcia-Morillo, M.
Font, C.
Samoon, Z.
Jabbar, A.A.
Kourie, H.R.
Kayumba, A.
Esposito, F.
Popescu, R.A.
García. Gómez, Jesús
Heyman, L.
Smit, T.
Krendyukov, A.
Mathieson, N.
Cooksley, T.
Anderson, R.
Klastersky, J.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Humans
Middle Aged
Prospective Studies
Neoplasms
Granulocyte Colony-Stimulating Factor
Medical Oncology
Febrile Neutropenia
Antineoplastic Combined Chemotherapy Protocols
AS Ourense
CHUO
topic Humans
Middle Aged
Prospective Studies
Neoplasms
Granulocyte Colony-Stimulating Factor
Medical Oncology
Febrile Neutropenia
Antineoplastic Combined Chemotherapy Protocols
AS Ourense
CHUO
description Purpose: Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10-20%) of FN would develop ? 1 episode of FN with a commonly used chemotherapy regimen in clinical practice. Methods: This prospective, real-world, observational, multinational, multicenter study (December 2016-October 2019) recruited patients with solid tumors or Hodgkin's/non-Hodgkin's lymphoma. Patients receiving chemotherapy with intermediate risk of FN, but not G-CSF as primary prophylaxis were included and observed for the duration of the chemotherapy (? 6 cycles and ? 30 days after the last chemotherapy administration). Results: In total, 364 patients (median age, 56 years) with 1601 cycles of chemotherapy were included in the analysis. The incidence of FN was 5% in cycle 1, 3% in cycles 2-3, and 1% in cycles 4-6. The rate of patients with ? 1 episode of FN was 9%, and 59% of FN events were reported during cycle 1. The rate of grade 4 neutropenia in cycle 1 was 11%, and 15% of patients experienced ? 1 episode of grade 4 neutropenia. Conclusions: Overall, the incidence of FN was low, with a high incidence in cycle 1 and a decrease in the subsequent cycles. These results provide the real FN risk for common chemotherapy regimens in patients generally excluded from clinical trials. Prophylactic G-CSF in intermediate-risk patients could be considered as per clinician's judgement.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/6550da4c92517a5a7db95456
http://hdl.handle.net/20.500.11940/20999
url https://portalcientifico.sergas.gal//documentos/6550da4c92517a5a7db95456
http://hdl.handle.net/20.500.11940/20999
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403008556597248
score 15,812429

Similares en LA Referencia